Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1982-6-24
|
| pubmed:abstractText |
More than a dozen compounds are now available. Although very effective and generally safe, the cephalosporins are often misused. The second- and third-generation drugs have provided progressively wider spectra of activity, although none has surpassed the activity of cephalothin against beta-lactamase-producing staphylococci. Cefotaxime and moxalactam have been shown to be useful in meningitis, whereas most of their predecessors have shown poor penetration into the cerebrospinal fluid.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0002-838X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
177-83
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
1982
|
| pubmed:articleTitle |
Cephalosporins: bridging the generation gap.
|
| pubmed:publicationType |
Journal Article
|